A citation-based method for searching scientific literature

Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
Times Cited: 253



Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John P H Wilding, Marc S Sabatine. Lancet 2019
Times Cited: 830




List of shared articles



Times cited

Effectiveness and Safety of SGLT2 Inhibitors in Clinical Routine Treatment of Patients with Diabetes Mellitus Type 2.
Maximilian Hopf, Christof Kloos, Gunter Wolf, Ulrich Alfons Müller, Nicolle Müller. J Clin Med 2021
0

Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome.
Muhammad Imtiaz Ahmad, Michael D Shapiro. Curr Atheroscler Rep 2021
0

Hypertension: Current trends and future perspectives.
Paul G Hunter, Fiona A Chapman, Neeraj Dhaun. Br J Clin Pharmacol 2021
0

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics.
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, Xueying Zheng, Sihui Luo, Peter J Little, Danielle Kamato, Amirhossein Sahebkar, Weiming Wu, Jianping Weng,[...]. Theranostics 2021
0

Timely and individualized heart failure management: need for implementation into the new guidelines.
Amr Abdin, Johann Bauersachs, Norbert Frey, Ingrid Kindermann, Andreas Link, Nikolaus Marx, Mitja Lainscak, Jonathan Slawik, Christian Werner, Jan Wintrich,[...]. Clin Res Cardiol 2021
0




Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease.
Kazuomi Kario, Keith C Ferdinand, James H O'Keefe. Prog Cardiovasc Dis 2020
12

Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Ona Kinduryte Schorling, Douglas Clark, Isabella Zwiener, Stefan Kaspers, Jisoo Lee, Hristo Iliev. Adv Ther 2020
2

New and emerging cardiovascular and antihypertensive drugs.
Steven G Chrysant, George S Chrysant. Expert Opin Drug Saf 2020
1

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Muhammad Shahzeb Khan, Muthiah Vaduganathan. Curr Diab Rep 2020
0

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Tadashi Toyama, Brendon L Neuen, Min Jun, Toshiaki Ohkuma, Bruce Neal, Meg J Jardine, Hiddo L Heerspink, Muh Geot Wong, Toshiharu Ninomiya, Takashi Wada,[...]. Diabetes Obes Metab 2019
63

Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy.
Anja Schork, Janine Saynisch, Andreas Vosseler, Benjamin Assad Jaghutriz, Nils Heyne, Andreas Peter, Hans-Ulrich Häring, Norbert Stefan, Andreas Fritsche, Ferruh Artunc. Cardiovasc Diabetol 2019
49

SGLT2 inhibitors for the treatment of diabetes: a patent review (2013-2018).
Jyotsana Pandey, Akhilesh K Tamrakar. Expert Opin Ther Pat 2019
6


Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence.
Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E Ochoa-Martinez, Yamely Mendez, Chelsea H Chang, Salim Surani. World J Diabetes 2019
6


Use of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: An Asian perspective and expert recommendations.
Chaicharn Deerochanawong, Siew P Chan, Bien J Matawaran, Wayne H-H Sheu, Juliana Chan, Nguyen H Man, Ketut Suastika, Chin M Khoo, Kun-Ho Yoon, Andrea Luk,[...]. Diabetes Obes Metab 2019
12


Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study.
Shih-Chieh Shao, Kai-Cheng Chang, Ming-Jui Hung, Ning-I Yang, Yuk-Ying Chan, Hui-Yu Chen, Yea-Huei Kao Yang, Edward Chia-Cheng Lai. Cardiovasc Diabetol 2019
17

Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials.
Atsunori Kashiwagi, Marina V Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida, John P H Wilding. Diabetes Ther 2019
3

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician's Guide.
Bryce C Simes, Gordon G MacGregor. Diabetes Metab Syndr Obes 2019
10

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
20